David A. Siegel Sutro Biopharma, Inc. Transaction History

Two Sigma Advisers, LP

$47 Billion
Q3 2025

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Sutro Biopharma, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 239,400 shares of STRO stock, worth $227,430. This represents 0.0% of its overall portfolio holdings.

Number of Shares

239,400

Previous 66,300 261.09%

Holding current value

$227,430

Previous $47,000 346.81%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$0.72 - $1.06 $124,632 - $183,486	173,100 Added 261.09%	239,400 $210,000
Q2 2025 Aug 14, 2025	SELL	$0.52 - $1.3 $90,792 - $226,980	-174,600 Reduced 72.48%	66,300 $47,000
Q1 2025 May 15, 2025	SELL	$0.65 - $2.12 $199,485 - $650,628	-306,900 Reduced 56.02%	240,900 $156,000
Q4 2024 Feb 14, 2025	SELL	$1.82 - $4.4 $78,442 - $189,640	-43,100 Reduced 7.29%	547,800 $1.01 Million
Q3 2024 Nov 14, 2024	SELL	$2.88 - $5.01 $275,328 - $478,956	-95,600 Reduced 13.93%	590,900 $2.04 Million

Q2 2024 Aug 14, 2024	BUY	$2.92 - $5.33 $44,968 - $82,082	15,400 Added 2.29%	686,500 $2.01 Million
Q1 2024 May 15, 2024	BUY	$3.27 - $5.65 $1.41 Million - $2.44 Million	431,300 Added 179.86%	671,100 $3.79 Million
Q4 2023 Feb 14, 2024	BUY	$2.07 - $4.54 $113,021 - $247,884	54,600 Added 29.48%	239,800 $1.03 Million
Q3 2023 Nov 14, 2023	SELL	$3.29 - $4.9 $541,205 - $806,050	-164,500 Reduced 47.04%	185,200 $642,000
Q2 2023 Aug 14, 2023	SELL	$4.25 - $5.88 $304,300 - $421,008	-71,600 Reduced 17.0%	349,700 $1.63 Million
Q1 2023 May 15, 2023	BUY	$4.48 - $8.45 $171,136 - $322,790	38,200 Added 9.97%	421,300 $1.95 Million
Q4 2022 Feb 14, 2023	BUY	$5.41 - $8.08 $192,596 - $287,648	35,600 Added 10.24%	383,100 $3.1 Million
Q3 2022 Nov 14, 2022	BUY	$5.17 - $7.11 $449,790 - $618,570	87,000 Added 33.4%	347,500 $1.93 Million
Q2 2022 Aug 15, 2022	BUY	$3.41 - $8.95 $523,776 - $1.37 Million	153,600 Added 143.69%	260,500 $1.36 Million
Q1 2022 May 16, 2022	BUY	$7.78 - $15.31 $98,028 - $192,906	12,600 Added 13.36%	106,900 $879,000
Q4 2021 Feb 14, 2022	SELL	$14.25 - $23.53 $855,000 - $1.41 Million	-60,000 Reduced 38.89%	94,300 $1.4 Million
Q3 2021 Nov 15, 2021	BUY	$16.88 - $22.38 $1.05 Million - $1.39 Million	62,300 Added 67.72%	154,300 $2.92 Million
Q2 2021 Aug 16, 2021	BUY	$18.03 - $23.82 $580,566 - $767,004	32,200 Added 53.85%	92,000 $1.71 Million
Q1 2021 May 17, 2021	BUY	$20.29 - $27.54 $342,901 - $465,426	16,900 Added 39.39%	59,800 $1.36 Million
Q4 2020 Feb 16, 2021	BUY	$10.16 - $23.98 $11,176 - $26,378	1,100 Added 2.63%	42,900 $931,000
Q3 2020 Nov 16, 2020	BUY	$7.44 - $13.15 $310,992 - $549,670	41,800 New	41,800 $420,000

Others Institutions Holding STRO

# of Institutions

Shares Held

57.3M

Call Options Held

75K

Put Options Held

View Full List

About SUTRO BIOPHARMA, INC.

Ticker STRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,161,500
Market Cap $49.6M
Description
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-dr...

More about STRO

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account